{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:36:51Z","timestamp":1787798211969,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtha.2025.05.030","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:15:31Z","timestamp":1749467731000},"page":"2819-2829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents"],"prefix":"10.1016","volume":"23","author":[{"given":"Gavin T.","family":"Buckley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-1227","authenticated-orcid":false,"given":"Maeve P.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3817-3658","authenticated-orcid":false,"given":"James V.","family":"Harte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.05.030_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13643-022-02098-w","article-title":"Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences","volume":"11","author":"Khouja","year":"2022","journal-title":"Syst Rev"},{"key":"10.1016\/j.jtha.2025.05.030_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for US Medicare beneficiaries","volume":"4","author":"Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2025.05.030_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4059","article-title":"Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010-2020","volume":"6","author":"Iyer","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2025.05.030_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.030_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.030_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.030_bib7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.05.030_bib8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.05.030_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.05.030_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib11","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.05.030_bib12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.05.030_bib13","article-title":"Factor XI inhibitors: the ongoing search for anticoagulation strategies in the prevention of arterial thromboembolism in cardiac and cerebrovascular disease","volume":"51","author":"Porres-Aguilar","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jtha.2025.05.030_bib14","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.05.030_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/hematology.2021000241","article-title":"Direct oral anticoagulant (DOAC) interference in hemostasis assays","volume":"2021","author":"Moser","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2025.05.030_bib16","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/diagnostics14171991","article-title":"Laboratory evaluation of interferences associated with factor XIa inhibitors asundexian and milvexian in routine coagulation assays","volume":"14","author":"Buckley","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jtha.2025.05.030_bib17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40262-022-01110-9","article-title":"Single-dose pharmacokinetics of milvexian in participants with mild or moderate hepatic impairment compared with healthy participants","volume":"61","author":"Perera","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2025.05.030_bib18","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.05.030_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117565","article-title":"Removing direct oral factor Xa inhibitor interferences from routine and specialised coagulation assays using a raw activated charcoal product","volume":"550","author":"Buckley","year":"2023","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jtha.2025.05.030_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/ijlh.14222","article-title":"Precision-weighing of raw activated charcoal using a 3D-printed micromeasure for the removal of direct oral anticoagulant-associated interferences in coagulation testing","volume":"46","author":"Buckley","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.05.030_bib21","first-page":"807","article-title":"Reference change values","volume":"50","author":"Fraser","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2025.05.030_bib22","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1515\/cclm-2022-1207","article-title":"Systematic review and meta-analysis of within-subject and between-subject biological variation data of coagulation and fibrinolytic measurands","volume":"61","author":"Hollestelle","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2025.05.030_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12959-023-00501-7","article-title":"The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review","volume":"21","author":"Frackiewicz","year":"2023","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2025.05.030_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/labmed1010006","article-title":"Ciraparantag does not remove anticoagulant activities in vitro, but DOAC-Stop may mitigate ciraparantag-associated interferences in coagulation testing","volume":"1","author":"Harte","year":"2024","journal-title":"LabMed"},{"key":"10.1016\/j.jtha.2025.05.030_bib25","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/jth.13486","article-title":"Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter\/multiplatform study","volume":"14","author":"Testa","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib26","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jth.14532","article-title":"subcommittee on plasma coagulation inhibitors. Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH","volume":"17","author":"Moore","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/10760296241241524","article-title":"Challenges to laboratory monitoring of direct oral anticoagulants","volume":"30","author":"Qiao","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ijlh.13196","article-title":"The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays","volume":"42","author":"Exner","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.05.030_bib29","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/jth.14488","article-title":"Resolving DOAC interference on APTT, PT, and lupus anticoagulant testing by the use of activated carbon","volume":"17","author":"Frans","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ijlh.12950","article-title":"Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban","volume":"41","author":"Platton","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.05.030_bib31","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1515\/cclm-2018-1197","article-title":"The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants","volume":"57","author":"Z\u0105bczyk","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2025.05.030_bib32","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"22","author":"Levy","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.thromres.2018.01.047","article-title":"Simple method for removing DOACs from plasma samples","volume":"163","author":"Exner","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.05.030_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ijlh.12807","article-title":"The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays","volume":"40","author":"Jacquemin","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.05.030_bib35","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1515\/cclm-2018-0967","article-title":"Effect of an activated charcoal product (DOAC StopT) intended for extracting DOACs on various other APTT-prolonging anticoagulants","volume":"57","author":"Exner","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2025.05.030_bib36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/rth2.12264","article-title":"The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: can activated carbon eliminate false-positive results?","volume":"4","author":"De Kesel","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib37","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for Lupus Anticoagulant\/Antiphospholipid Antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib38","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for Lupus Anticoagulant\/Antiphospholipid Antibodies of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Tripodi","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1538-7836.2010.04098.x","article-title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays","volume":"9","author":"Hillarp","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-06-0342","article-title":"Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays","volume":"105","author":"Lindahl","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib41","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jth.12649","article-title":"Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays","volume":"12","author":"Hillarp","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.05.030_bib42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/00365513.2018.1522664","article-title":"Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays","volume":"78","author":"Hillarp","year":"2018","journal-title":"Scand J Clin Lab Invest"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500354X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500354X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:04:16Z","timestamp":1778868256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362500354X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S153878362500354X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.030","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.032","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}